-- A new research document with title 'OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Gilead Sciences, Novo Nordisk, Immuron etc. The report will help user gain market insights, future trends and growth prospects for forecast period of 2016 – 2026.
Request a sample report @ https://www.htfmarketreport.com/sample-report/633887-opportunityanalyzer-18
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and it is therefore a potentially fatal condition.
Analyst estimates the 2016 sales for the NASH market at approximately $618m across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the NASH market will grow at a Compound Annual Growth Rate (CAGR) of 45.0% across the 7MM. The US and Japanese markets are both anticipated to grow significantly, recording CAGRs of 48.1% and 50.7%, respectively, while the 5EU will record a CAGR of 30.6%. At the end of 2026, the US will account for around 88% of global sales, while the 5EU and Japan will account for around 10% and 2% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of NASH in the region, as well as the launch of more pipeline agents in this region.
Key Questions Answered
- How will the NASH market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2016-2026?
- What are the most promising late-stage pipeline drugs in NASH?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the greatest unmet needs in NASH? Will the pipeline drugs fulfil these needs of the market?
- What are the biggest opportunities in the NASH landscape?
Scope
- Overview of NASH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline NASH market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting NASH therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global NASH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=633887
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NASH therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Companies Mentioned in the Report
Gilead Sciences
Intercept Pharmaceuticals
Genfit SA
Allergan Plc
Galectin Therapeutics
Galmed Pharmaceuticals
Inventiva Pharma
Novo Nordisk
Conatus Pharmaceuticals
Novartis
Immuron Limited
Cirius Therapeutics
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/633887-opportunityanalyzer-18
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Executive Summary 7
2.1 Mid-Forecast Surge in Sales for NASH 7
2.2 Manufacturers Are Employing Strategies to Improve Diagnostics while Advancing Drug Development 9
2.3 Vast Unmet Needs Exist in the NASH Market 9
2.4 Opportunities Abound for Tools that Support Accurate Diagnosis 9
2.5 Launches of Novel Pipeline Products Will Revolutionize the NASH Treatment Landscape 10
2.6 What Do the Physicians Think? 12
3 Introduction 15
3.1 Catalyst 15
3.2 Related Reports 15
4 Disease Overview 16
4.1 Etiology and Pathophysiology 16
4.1.1 Etiology 16
4.1.2 Pathophysiology 17
4.2 Disease Staging 22
4.3 Symptoms 23
5 Epidemiology 24
5.1 Risk Factors and Comorbidities 24
5.2 Global Trends 26
5.2.1 US 27
5.2.2 5EU 27
5.2.3 Japan 28
5.3 Forecast Methodology 28
5.3.1 Sources Used Tables 30
5.3.2 Forecast Assumptions and Methods 33
5.3.3 Sources Not Used 41
5.4 Epidemiological Forecast for NASH (2016-2026) 42
5.4.1 Total Prevalent Cases of NASH 42
5.4.2 Age-Specific Total Prevalent Cases of NASH 44
5.4.3 Sex-Specific Total Prevalent Cases of NASH 45
5.4.4 Age-Standardized Prevalence of NASH 47
5.4.5 Diagnosed Prevalent Cases of NASH 48
5.4.6 Diagnosed Prevalent Cases of NASH by Comorbid Disorder 50
5.5 Discussion 52
....Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/633887-opportunityanalyzer-18
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Info:
Name: Craig Francis
Email: Send Email
Organization: HTF Market Intelligence Consulting Pvt. Ltd.
Address: Unit No. 429, Parsonage Road Edison, NJ
Phone: +1 (206) 317 1218
Website: https://www.htfmarketreport.com/reports/633887-opportunityanalyzer-18
Release ID: 421612
Google
RSS